Expression of EVI1 gene and its clinical significance in pediatric acute myeloid leukemia
10.3969/j.issn.1000-3606.2017.05.003
- VernacularTitle:EVI1基因在儿童急性髓细胞白血病中的表达及意义
- Author:
Chenyu ZHENG
;
Xianhao WEN
;
Yuxia GUO
;
Xianmin GUAN
;
Jie YU
;
Jianwen XIAO
- Keywords:
acute myeloid leukemia;
EVI1 gene;
prognosis;
child
- From:
Journal of Clinical Pediatrics
2017;35(5):331-335
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between EVI1 gene expression and clinical features and prognosis of children with acute myeloid leukemia (AML). Methods EVI1 gene was detected in AML children, correlation of clinical and lab features, prognosis of AML children with EVI1 gene were analyzed. Results EVI1 expression is positive in 38 of 145 children with AML. There were no significant differences in age, gender, hemoglobin concentration, leukocytes and platelet count, subtype of morphology, ratio of chromosomal anomaly and complex karyotypes between EVI1 positive and EVI1 negative group (P>0.05); coexist genes were detected in 9 cases (23.68%) of EVI1 positive group. Rate of complete remission (CR) was 91.67% in 24 cases of EVI1 positive patients received chemotherapy. Relapse rate was 64.29% and 14.29% in EVI1 positive patients who received chemotherapy and allo-hematopoietic stem cell transplantation (allo-HSCT), retrospectively and significant differences were found (P<0.05). There was no significant difference in CR but significant difference was found in event free survival (P<0.05) for EVI1 positive and EVI1 negative patients who received chemotherapy. EVI1 gene kept negative when bone marrow relapse occurred in two patients with EVI1 positive at diagnosis. Conclusion EVI1 gene may play adverse role in pediatric AML; prognosis of EVI1 positive AML patients can be improved by allo-HSCT; follow-up of EVI1 transcript levels is insufficient to monitoring of minimal residual disease.
